Tyr397
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr397  -  FAK (human)

Site Information
sVsEtDDyAEIIDEE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447887
Available spectra:  5 CST
Associated spectra:  7 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 24 , 55 ) , immunoprecipitation ( 3 , 4 , 5 , 7 , 8 , 10 , 14 , 15 , 22 , 23 , 31 , 37 , 49 , 106 , 123 , 159 , 537 , 543 , 544 ) , mass spectrometry ( 18 , 32 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 50 , 53 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 70 , 71 , 72 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 94 , 95 , 96 , 97 , 98 , 99 , 102 , 103 , 104 , 107 , 108 , 112 , 113 , 114 , 115 , 116 , 117 , 119 , 120 , 121 , 124 , 125 , 128 , 130 , 131 , 134 , 135 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 156 , 157 , 158 , 160 , 161 , 162 , 163 , 164 , 165 , 166 , 167 , 168 , 169 , 170 , 171 , 172 , 173 , 174 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 190 , 191 , 192 , 193 , 194 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 206 , 207 , 208 , 209 , 210 , 211 , 212 , 213 , 215 , 216 , 217 , 218 , 219 , 220 , 221 , 222 , 223 , 224 , 225 , 226 , 227 , 228 , 229 , 231 , 232 , 233 , 235 , 236 , 241 , 242 , 243 , 244 , 250 , 251 , 252 , 253 , 254 , 255 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 267 , 271 , 272 , 273 , 274 , 275 , 276 , 277 , 278 , 279 , 280 , 282 , 283 , 284 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 293 , 294 , 295 , 296 , 297 , 298 , 299 , 300 , 301 , 302 , 303 , 304 , 305 , 306 , 308 , 309 , 310 , 311 , 312 , 313 , 314 , 315 , 316 , 317 , 318 , 319 , 320 , 321 , 322 , 323 , 324 , 325 , 326 , 327 , 329 , 330 , 331 , 332 , 333 , 334 , 335 , 336 , 337 , 338 , 339 , 340 , 341 , 342 , 343 , 344 , 345 , 347 , 348 , 350 , 355 , 356 , 357 , 359 , 360 , 361 , 362 , 363 , 364 , 365 , 366 , 367 , 369 , 372 , 373 , 375 , 376 , 377 , 378 , 379 , 381 , 382 , 383 , 384 , 385 , 386 , 387 , 388 , 389 , 390 , 391 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 402 , 403 , 404 , 405 , 407 , 408 , 409 , 411 , 412 , 413 , 414 , 415 , 416 , 417 , 418 , 419 , 421 , 422 , 423 , 424 , 425 , 426 , 427 , 428 , 429 , 430 , 431 , 432 , 433 , 434 , 435 , 436 , 437 , 439 , 440 , 441 , 445 , 446 , 447 , 450 , 452 , 453 , 455 , 456 , 457 , 459 , 460 , 461 , 462 , 465 , 466 , 467 , 468 , 469 , 471 , 472 , 473 , 474 , 475 , 476 , 477 , 478 , 479 , 480 , 481 , 482 , 483 , 484 , 485 , 486 , 488 , 489 , 490 , 491 , 492 , 493 , 494 , 497 , 498 , 501 , 548 ) , microscopy-colocalization with upstream kinase ( 123 ) , mutation of modification site ( 2 , 3 , 4 , 9 , 10 , 13 , 15 , 19 , 23 , 31 , 33 , 106 , 237 , 238 , 239 , 352 , 354 , 358 , 406 , 444 , 448 , 458 , 470 , 495 , 509 , 511 , 523 , 537 , 541 , 543 , 544 , 545 ) , phospho-antibody ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 19 , 21 , 23 , 24 , 25 , 26 , 28 , 29 , 30 , 31 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 48 , 49 , 51 , 52 , 54 , 55 , 56 , 57 , 74 , 75 , 76 , 77 , 78 , 93 , 100 , 101 , 105 , 106 , 109 , 111 , 118 , 122 , 123 , 126 , 127 , 129 , 132 , 133 , 136 , 137 , 155 , 159 , 188 , 189 , 205 , 214 , 230 , 237 , 238 , 239 , 245 , 246 , 247 , 248 , 249 , 266 , 268 , 269 , 270 , 281 , 307 , 346 , 349 , 351 , 352 , 353 , 354 , 358 , 368 , 370 , 371 , 374 , 380 , 401 , 406 , 410 , 420 , 438 , 442 , 443 , 444 , 448 , 449 , 451 , 454 , 458 , 463 , 464 , 470 , 487 , 495 , 496 , 499 , 500 , 502 , 503 , 504 , 505 , 506 , 507 , 508 , 509 , 510 , 511 , 512 , 513 , 514 , 515 , 516 , 517 , 518 , 519 , 520 , 521 , 522 , 523 , 524 , 525 , 526 , 527 , 528 , 529 , 530 , 531 , 532 , 533 , 534 , 535 , 536 , 537 , 538 , 539 , 540 , 541 , 542 , 545 , 546 , 547 ) , phosphoamino acid analysis ( 240 ) , western blotting ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 19 , 21 , 23 , 24 , 25 , 26 , 28 , 29 , 30 , 31 , 34 , 35 , 36 , 37 , 38 , 39 , 48 , 49 , 51 , 52 , 54 , 55 , 56 , 57 , 74 , 75 , 76 , 77 , 78 , 93 , 100 , 101 , 105 , 106 , 109 , 111 , 118 , 122 , 123 , 127 , 129 , 132 , 133 , 136 , 137 , 155 , 159 , 188 , 189 , 205 , 214 , 230 , 238 , 239 , 240 , 245 , 246 , 247 , 248 , 249 , 268 , 270 , 281 , 307 , 349 , 351 , 352 , 353 , 354 , 358 , 368 , 370 , 371 , 374 , 380 , 401 , 406 , 438 , 444 , 448 , 454 , 458 , 463 , 487 , 495 , 499 , 502 , 503 , 504 , 506 , 507 , 513 , 514 , 517 , 520 , 525 , 533 , 535 , 537 , 538 , 540 , 541 , 542 , 543 , 544 , 545 , 546 , 547 )
Disease tissue studied:
adenoid cystic carcinoma ( 191 , 192 ) , bile-duct cancer ( 181 ) , bladder cancer ( 278 , 279 , 310 ) , bone cancer ( 36 , 51 , 235 , 236 , 244 , 406 , 447 ) , osteosarcoma ( 235 , 236 , 244 , 406 , 447 ) , brain cancer ( 53 , 75 , 86 , 93 , 103 , 122 , 139 , 214 , 327 , 377 , 378 , 379 , 389 , 390 , 430 , 495 ) , astrocytoma ( 86 , 327 , 430 ) , glioblastoma ( 75 , 93 , 103 , 122 , 139 , 377 , 378 , 379 , 389 , 390 , 495 ) , glioblastoma multiforme ( 53 , 93 , 378 , 389 , 390 ) , glioma ( 53 , 75 , 93 , 103 , 122 , 139 , 377 , 378 , 379 , 389 , 390 , 495 ) , breast cancer ( 4 , 7 , 9 , 11 , 23 , 38 , 40 , 78 , 123 , 126 , 129 , 133 , 159 , 169 , 188 , 237 , 240 , 274 , 275 , 276 , 285 , 286 , 287 , 288 , 289 , 290 , 291 , 292 , 297 , 308 , 311 , 334 , 335 , 349 , 381 , 382 , 383 , 391 , 418 , 419 , 440 , 441 , 456 , 457 , 501 , 504 ) , breast adenocarcinoma ( 38 , 382 , 501 ) , breast ductal carcinoma ( 383 ) , HER2 positive breast cancer ( 18 ) , luminal A breast cancer ( 18 ) , luminal B breast cancer ( 18 ) , breast cancer, triple negative ( 18 , 38 , 289 , 290 , 381 , 383 , 391 ) , colorectal cancer ( 26 , 28 , 70 , 71 , 72 , 84 , 85 , 92 , 246 , 249 , 270 , 281 , 316 , 318 , 342 , 343 , 344 , 347 , 348 , 356 , 357 , 366 , 367 , 371 , 386 , 405 , 409 , 428 , 429 , 432 , 433 , 438 , 448 , 467 , 468 , 474 , 475 , 492 , 493 , 510 , 520 ) , colorectal carcinoma ( 26 , 28 , 70 , 71 , 72 , 84 , 85 , 92 , 246 , 249 , 270 , 281 , 316 , 318 , 342 , 343 , 344 , 347 , 348 , 356 , 357 , 366 , 367 , 386 , 405 , 409 , 428 , 429 , 432 , 433 , 438 , 448 , 467 , 468 , 474 , 475 , 492 , 493 , 520 ) , esophageal cancer ( 174 , 300 , 301 , 302 , 319 , 320 , 321 , 329 , 330 , 331 , 332 , 359 , 360 , 361 , 364 ) , esophageal carcinoma ( 300 , 301 , 302 , 329 , 330 , 332 ) , esophageal cancer, surrounding tissue ( 173 ) , gallbladder cancer ( 187 ) , gastric cancer ( 30 , 66 , 67 , 68 , 131 , 134 , 140 , 142 , 143 , 145 , 146 , 147 , 195 , 215 , 216 , 217 , 218 , 219 , 223 , 224 , 225 , 226 , 227 , 255 , 298 , 345 ) , gastric carcinoma ( 30 , 66 , 67 , 68 , 134 , 195 , 218 , 255 , 345 ) , gastric carcinoma, surrounding tissue ( 141 , 144 , 194 ) , HNSCC ( 57 ) , kidney cancer ( 277 ) , leukemia ( 372 , 487 , 543 ) , acute myelogenous leukemia ( 372 , 487 ) , liver cancer ( 14 , 25 , 37 , 132 , 154 , 158 , 161 , 162 , 176 , 182 , 186 , 197 , 206 , 208 , 209 , 352 ) , liver adenocarcinoma ( 132 ) , cholangiocellular carcinoma ( 352 ) , hepatocellular carcinoma ( 14 , 25 , 37 , 132 , 154 , 158 , 161 , 162 , 176 , 206 , 209 ) , hepatocellular carcinoma, surrounding tissue ( 156 , 157 , 175 , 207 ) , lung cancer ( 5 , 31 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 49 , 55 , 60 , 61 , 62 , 63 , 64 , 65 , 74 , 76 , 77 , 79 , 80 , 81 , 82 , 83 , 87 , 88 , 89 , 90 , 91 , 94 , 95 , 96 , 97 , 98 , 99 , 109 , 111 , 125 , 128 , 134 , 138 , 149 , 150 , 151 , 163 , 164 , 165 , 166 , 167 , 168 , 177 , 178 , 179 , 185 , 196 , 211 , 212 , 222 , 229 , 230 , 248 , 250 , 251 , 252 , 253 , 254 , 256 , 257 , 258 , 259 , 260 , 261 , 262 , 263 , 264 , 265 , 267 , 268 , 271 , 272 , 273 , 280 , 291 , 292 , 299 , 312 , 313 , 314 , 315 , 322 , 323 , 324 , 325 , 326 , 336 , 337 , 338 , 339 , 340 , 341 , 365 , 369 , 373 , 375 , 376 , 384 , 387 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 402 , 403 , 404 , 408 , 411 , 412 , 413 , 414 , 415 , 416 , 421 , 422 , 424 , 426 , 427 , 431 , 435 , 437 , 439 , 445 , 446 , 450 , 453 , 454 , 455 , 459 , 460 , 461 , 462 , 480 , 481 , 482 , 484 , 485 , 486 , 488 , 489 , 490 , 491 , 497 , 514 , 535 , 547 ) , non-small cell lung cancer ( 5 , 31 , 41 , 42 , 43 , 45 , 46 , 47 , 49 , 50 , 55 , 60 , 61 , 62 , 63 , 64 , 65 , 79 , 80 , 81 , 82 , 83 , 87 , 88 , 89 , 90 , 91 , 94 , 95 , 96 , 97 , 98 , 99 , 125 , 138 , 149 , 150 , 151 , 163 , 164 , 165 , 177 , 185 , 196 , 211 , 212 , 222 , 229 , 230 , 250 , 254 , 256 , 257 , 258 , 259 , 261 , 262 , 263 , 264 , 265 , 267 , 271 , 273 , 299 , 312 , 313 , 314 , 315 , 322 , 323 , 324 , 325 , 326 , 336 , 337 , 338 , 339 , 340 , 341 , 365 , 369 , 373 , 376 , 384 , 387 , 392 , 393 , 394 , 395 , 396 , 397 , 398 , 399 , 400 , 402 , 403 , 404 , 411 , 412 , 413 , 414 , 415 , 416 , 421 , 424 , 426 , 427 , 435 , 437 , 439 , 445 , 450 , 453 , 454 , 455 , 459 , 460 , 461 , 462 , 480 , 481 , 482 , 484 , 485 , 486 , 488 , 489 , 490 , 491 , 497 ) , non-small cell lung adenocarcinoma ( 5 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 50 , 55 , 81 , 82 , 83 , 89 , 90 , 91 , 94 , 95 , 96 , 97 , 98 , 99 , 134 , 138 , 149 , 150 , 163 , 164 , 177 , 196 , 211 , 212 , 222 , 229 , 254 , 256 , 257 , 263 , 264 , 265 , 280 , 291 , 292 , 400 , 414 ) , non-small cell large cell lung carcinoma ( 31 , 42 , 45 ) , non-small cell squamous cell lung carcinoma ( 44 , 134 , 166 , 167 , 168 , 178 , 179 , 222 , 256 , 257 , 373 , 392 , 395 , 403 , 404 , 437 , 489 ) , small-cell lung cancer ( 111 , 375 , 422 , 514 ) , lymphoma ( 507 ) , nasopharyngeal carcinoma ( 34 ) , neuroblastoma ( 32 , 127 , 214 , 283 , 284 , 293 , 294 , 295 , 546 ) , ovarian cancer ( 40 , 104 , 112 , 113 , 114 , 115 , 116 , 118 , 120 , 121 , 242 , 350 , 355 , 385 ) , ovarian epithelial carcinoma ( 40 , 104 ) , pancreatic cancer ( 13 , 27 , 152 , 153 , 205 , 465 , 466 , 471 , 472 , 473 , 476 , 477 , 483 ) , pancreatic carcinoma ( 13 , 27 , 152 , 153 , 205 , 465 , 466 , 471 , 472 , 473 , 476 , 477 , 483 ) , multiple myeloma ( 21 ) , prostate cancer ( 24 , 245 , 368 , 469 , 494 , 538 ) , melanoma skin cancer ( 2 , 129 , 180 ) , non-melanoma skin cancer ( 478 , 479 ) , cancer, squamous cell carcinoma ( 57 , 502 , 505 ) , ventricular tachycardia ( 102 )
Relevant cell line - cell type - tissue:
'liver, para-cholangiocellular carcinoma tissue' ( 107 ) , 143.98.2 (bone cell) ( 244 ) , 143B (bone cell) ( 236 ) , 184A1 (epithelial) [HER2 (human), transfection] ( 303 ) , 184A1 (epithelial) ( 303 ) , 23132/87 (gastric) ( 345 ) , 293 (epithelial) [EFNB1 (human), transfection] ( 135 ) , 293 (epithelial) [EphB2 (human), transfection] ( 135 ) , 293 (epithelial) ( 7 , 8 , 22 , 106 , 123 , 266 , 354 , 420 , 499 , 527 , 537 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 266 , 451 , 470 , 509 , 524 , 532 ) , 3T3 (fibroblast) ( 52 , 240 , 444 , 544 ) , 5637 (bladder cell) ( 310 ) , 639V (renal) ( 277 ) , A375 (melanocyte) ( 2 ) , A431 (epithelial) [FAK (human)] ( 247 ) , A431 (epithelial) ( 478 , 479 ) , A498 (renal) ( 124 ) , A549 (pulmonary) [LKB1 (human), no information] ( 212 ) , A549 (pulmonary) ( 41 , 55 , 74 , 76 , 109 , 163 , 211 , 230 , 248 , 251 , 252 , 253 , 260 , 268 , 431 , 454 , 497 , 535 ) , ACC-S (adenoidal) ( 190 ) , ACN ( 32 , 294 ) , AU565 (breast cell) ( 285 , 286 ) , AZ-521 (gastric) ( 216 ) , BAEC (endothelial) ( 458 , 530 ) , BEL7402 (hepatic) ( 25 ) , BGC823 (gastric) ( 30 ) , BPAEC ( 353 , 522 ) , breast ( 18 , 297 , 311 ) , BT-474 (breast cell) ( 169 , 511 ) , BxPC-3 (pancreatic) ( 13 , 266 ) , C4-2B (prostate cell) ( 24 ) , C8161 (melanocyte) ( 129 ) , Caco-2 (intestinal) ( 270 , 410 ) , Caki-2 (renal) ( 309 ) , Cal-12T (pulmonary) ( 47 ) , CAL-29 (bladder cell) ( 279 ) , CAL-51 (breast cell) ( 287 , 288 ) , Calu-3 (pulmonary) ( 43 , 446 , 454 ) , Caov-3 (ovarian) ( 40 ) , Capan1 (pancreatic) ( 13 , 27 ) , CD18/HPAF (pancreatic) ( 27 ) , CHO (fibroblast) [EphB1 (human), transfection] ( 537 ) , CHO (fibroblast) ( 16 , 444 ) , COLO-680N (esophageal) ( 331 ) , colon ( 510 ) , COS (fibroblast) ( 374 , 406 , 449 , 519 , 532 , 545 ) , COS7 (fibroblast) ( 9 ) , DBTRG-05MG (glial) ( 389 ) , DMS153 (pulmonary) ( 46 ) , DMS53 (pulmonary) ( 422 ) , DU 145 (prostate cell) ( 494 , 538 ) , DU4475 (breast cell) ( 500 ) , EFM-19 (breast cell) ( 317 ) , EFO-21 (ovarian) ( 355 ) , endothelial ( 17 ) , endothelial-pulmonary artery ( 442 ) , epithelial-prostate ( 368 ) , esophagus ( 173 , 174 ) , EVSA-T (breast cell) ( 334 ) , FaDu (squamous) ( 57 ) , FG (pancreatic) ( 247 ) , fibroblast-foreskin ( 509 ) , FU-OV-1 (ovarian) ( 350 ) , FU97 (gastric) ( 131 ) , GI-CA-N (neural crest) ( 283 ) , GI-LI-N (neuron) ( 32 , 295 ) , GI-ME-N (neuron) ( 32 , 293 ) , glial-brain ( 53 ) , HBE (epithelial) ( 454 ) , HBL-100 (breast cell) ( 78 ) , HBMEC (endothelial) ( 541 ) , HCC1143 (breast cell) ( 383 ) , HCC1428 (breast cell) ( 382 ) , HCC15 (pulmonary) ( 44 ) , HCC1599 (breast cell) ( 274 ) , HCC1806 (breast cell) ( 391 ) , HCC1937 (breast cell) ( 381 ) , HCC366 (pulmonary) ( 426 ) , HCC44 (pulmonary) ( 47 , 416 ) , HCC70 (breast cell) ( 289 , 290 ) , HCC78 (pulmonary) ( 45 , 83 , 90 , 91 , 415 ) , HCC827 (pulmonary) ( 5 , 43 , 229 , 254 , 263 , 264 , 265 , 400 ) , HCT116 (intestinal) ( 26 , 28 , 70 , 71 , 72 , 84 , 85 , 92 , 316 , 344 , 432 , 433 , 467 , 468 ) , HCT15 (intestinal) ( 356 ) , HCT8 (intestinal) ( 357 ) , heart ( 102 , 213 , 540 ) , HEK293T (epithelial) ( 4 , 15 , 33 , 444 , 452 , 539 ) , HeLa (cervical) ( 2 , 8 , 33 , 39 , 48 , 56 , 198 , 202 , 203 , 204 ) , Hep 3B2.1-7 (hepatic) ( 14 , 132 ) , hepatic-'liver, para-hepatocellular carcinoma tissue' ( 156 , 157 , 175 , 207 ) , hepatocyte-liver ( 154 , 158 , 206 , 209 ) , HepG2 (hepatic) ( 25 , 132 , 162 , 526 ) , HES-3 ('stem, embryonic') ( 108 ) , HFF1 (fibroblast) ( 101 ) , HL60 (myeloid) [FAK (human), transfection] ( 543 ) , HLF (hepatic) ( 161 ) , HMEC (endothelial) ( 54 , 380 ) , HMVEC (endothelial) ( 351 ) , HOS (bone cell) ( 235 , 508 ) , HPAC (pancreatic) ( 153 ) , HPAEC (endothelial) ( 503 , 516 ) , Hs766T (pancreatic) ( 466 , 483 ) , HT-29 (intestinal) ( 281 , 347 , 348 , 409 , 428 , 429 , 434 , 474 , 475 , 492 , 493 , 531 ) , HT1080 (fibroblast) ( 508 ) , Huh1 (hepatic) ( 176 ) , Huh6 (hepatic) ( 197 ) , Huh7 (hepatic) ( 14 , 132 ) , HUVEC (endothelial) ( 19 , 34 , 136 , 189 , 193 , 346 , 370 , 463 , 512 , 528 , 533 , 537 , 542 ) , IEC-18 (epithelial) ( 249 , 266 ) , IGROV1 (ovarian) ( 515 ) , IM95 (gastric) ( 217 ) , IMR-90 (fibroblast) ( 508 , 513 ) , IOSE-29 (ovarian) ( 515 ) , JHH-5 (hepatic) ( 186 ) , JHH-6 (hepatic) ( 182 ) , JIMT-1 (breast cell) ( 308 , 335 ) , Jurkat (T lymphocyte) ( 220 , 221 , 228 , 231 , 232 , 233 ) , Kasumi-1 (myeloid) ( 372 ) , keratinocyte ( 6 ) , KG-1 (myeloid) ( 496 ) , Kyse140 (esophageal) ( 300 , 301 , 302 ) , Kyse270 (esophageal) ( 319 , 320 , 321 , 359 ) , Kyse410 (esophageal) ( 364 ) , Kyse450 (squamous) ( 361 ) , Kyse510 (esophageal) ( 360 ) , Kyse70 (esophageal) ( 329 , 330 , 332 ) , L3.6p1 (pancreatic) ( 247 ) , LAN-1 (neural crest) ( 284 ) , larynx ( 505 ) , LCLC-103H (pulmonary) ( 336 ) , liver ( 132 , 208 ) , LLC-PK1 (renal) ( 401 , 534 ) , LN18 (glial) ( 378 ) , LN229 (glial) ( 93 , 122 , 379 ) , LN405 (glial) ( 327 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFR (wildtype)] ( 103 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFRvIII mutant (aka Delta EGFR, d2-7 EGFR; del. exon 2-7; in-frame loss 801 bp/267 aa in EC domain)] ( 103 ) , LN428_LNZ308 (glial) [EGFR (human), transfection, EGFRvIII-ki mutant (deletion of exons 2-7 plus kinase inactive mutation)] ( 103 ) , LN444 (glial) ( 139 ) , LNCaP (prostate cell) ( 538 ) , LOU-NH91 (squamous) ( 44 , 373 , 395 ) , Ls174T (intestinal) ( 521 ) , lung ( 41 , 42 , 43 , 44 , 45 , 46 , 47 , 94 , 95 , 96 , 97 , 98 , 99 , 128 , 138 , 166 , 167 , 168 , 177 , 178 , 179 , 196 , 267 , 271 , 272 , 273 , 312 , 314 , 315 , 322 , 323 , 324 , 325 , 326 , 341 , 362 , 363 , 369 , 387 , 388 , 393 , 407 , 417 , 423 , 424 , 425 ) , LXF-289 (pulmonary) ( 337 ) , M059J (glial) ( 377 ) , macrophage-blood ( 449 ) , mammary gland ( 237 ) , MCF-10A (breast cell) [CSFR (human), transfection] ( 117 ) , MCF-10A (breast cell) ( 117 , 418 , 419 , 440 , 441 , 456 , 457 , 511 ) , MCF-7 (breast cell) [Src (human)] ( 349 ) , MCF-7 (breast cell) ( 23 , 40 , 123 , 133 , 159 , 237 , 443 , 501 , 511 ) , MDA-MB-231 (breast cell) [Syk (human), transfection, Tet-reponsive Syk-inducible system] ( 119 ) , MDA-MB-231 (breast cell) ( 4 , 7 , 9 , 11 , 119 , 129 , 240 , 500 ) , MDA-MB-361 (breast cell) ( 240 ) , MDA-MB-435S (breast cell) ( 160 ) , MDA-MB-468 (breast cell) ( 38 ) , MDCK (epithelial) ( 106 , 247 , 454 ) , MDCKII (epithelial) ( 3 ) , MEEC (epithelial) ( 54 ) , MEF (fibroblast) ( 5 , 52 , 214 , 352 ) , MEF (fibroblast) [FAK (human), transfection] ( 100 ) , MEF (fibroblast) [PTP1B (mouse)] ( 374 ) , mesangial-kidney ( 238 ) , MHCC97H (hepatic) ( 25 ) , MIA PaCa (pancreatic) ( 205 ) , MIA PaCa-2 (pancreatic) ( 13 , 471 , 472 , 473 ) , MKN-1 (gastric) ( 218 ) , MKN-45 (gastric) ( 66 , 67 , 68 , 134 , 255 ) , MKN-7 (gastric) ( 225 ) , MKN-74 (gastric) ( 226 ) , MNNG-HOS (bone cell) ( 447 ) , MT-3 (breast cell) ( 291 , 292 ) , MV4-11 (macrophage) ( 160 ) , myeloid ( 496 ) , myocyte-heart ( 10 , 506 , 540 ) , NBT-II (bladder cell) ( 464 ) , NCI-H1299 (pulmonary) ( 5 , 31 , 42 , 49 , 125 ) , NCI-H1355 (pulmonary) ( 41 ) , NCI-H1373 (pulmonary) ( 480 , 481 ) , NCI-H1435 (pulmonary) ( 384 ) , NCI-H1437 (pulmonary) ( 46 , 47 , 412 , 454 ) , NCI-H1568 (pulmonary) ( 411 ) , NCI-H1650 (pulmonary) ( 5 , 43 , 60 , 61 , 62 , 63 , 64 , 65 , 79 , 80 , 87 , 88 , 164 , 229 , 398 , 453 , 459 , 498 ) , NCI-H1666 (pulmonary) ( 47 , 229 , 399 , 445 , 450 , 461 ) , NCI-H1703 (squamous) ( 44 , 134 , 170 , 171 , 172 , 183 , 184 , 185 , 222 , 250 , 256 , 257 , 427 , 482 ) , NCI-H1734 (pulmonary) ( 42 , 229 , 394 , 462 ) , NCI-H1781 (pulmonary) ( 45 , 299 ) , NCI-H1792 (pulmonary) ( 41 , 454 ) , NCI-H1793 (pulmonary) ( 397 ) , NCI-H1869 (squamous) ( 392 ) , NCI-H1944 (pulmonary) ( 42 , 414 ) , NCI-H1975 (pulmonary) ( 43 , 455 , 460 ) , NCI-H2023 (pulmonary) ( 396 ) , NCI-H2030 (pulmonary) ( 376 ) , NCI-H2052 (pulmonary) ( 338 ) , NCI-H2066 (pulmonary) ( 365 ) , NCI-H2073 (pulmonary) ( 44 , 46 , 340 ) , NCI-H209 (pulmonary) ( 46 , 111 ) , NCI-H2106 (pulmonary) ( 43 ) , NCI-H2170 (squamous) ( 437 ) , NCI-H2172 (pulmonary) ( 402 ) , NCI-H2228 (pulmonary) ( 45 , 50 , 199 , 200 , 201 , 421 ) , NCI-H226 (pulmonary) ( 489 ) , NCI-H2286 (pulmonary) ( 375 ) , NCI-H23 (pulmonary) ( 41 , 150 ) , NCI-H2342 (pulmonary) ( 44 , 339 ) , NCI-H2347 (pulmonary) ( 435 ) , NCI-H2405 (pulmonary) ( 47 ) , NCI-H292 (pulmonary) ( 77 , 125 ) , NCI-H3122 (pulmonary) ( 45 , 81 , 82 , 89 ) , NCI-H3255 (pulmonary) ( 134 , 165 , 229 , 258 , 259 , 261 , 262 , 313 ) , NCI-H358 (pulmonary) ( 42 , 151 , 439 ) , NCI-H441 (pulmonary) ( 41 , 149 , 248 , 490 , 491 ) , NCI-H446 (pulmonary) ( 514 ) , NCI-H460 (pulmonary) ( 31 , 42 , 454 , 484 , 485 , 486 , 488 ) , NCI-H520 (squamous) ( 403 , 404 ) , NCI-H522 (pulmonary) ( 454 ) , NCI-H661 (pulmonary) ( 45 , 408 ) , NCI-H69 (pulmonary) ( 111 ) , NCI-H82 (pulmonary) ( 111 ) , NCI-H838 (pulmonary) ( 46 , 413 ) , NCI-H929 (B lymphocyte) ( 21 ) , NMuMG (epithelial) ( 155 ) , NOZ ('epithelial, gallbladder') ( 187 ) , NT2 (testicular) ( 130 ) , NUGC-2 (gastric) ( 223 ) , NUGC-3 (gastric) ( 219 ) , NUGC-4 (gastric) ( 224 ) , osteoblast-calvarium ( 358 ) , ovary ( 40 , 120 , 242 ) , OVCAR420 (ovarian) ( 118 ) , OVCAR8 (ovarian) ( 116 , 121 ) , OVKATE (ovarian) ( 112 ) , OVMANA (ovarian) ( 104 ) , OVMIU (ovarian) ( 114 ) , PANC-1 (pancreatic) ( 152 , 266 , 476 , 477 ) , PC3 (prostate cell) [CD82 (human)] ( 368 ) , PC3 (prostate cell) ( 24 , 245 , 247 , 368 , 469 , 538 ) , PC9 (pulmonary) ( 333 ) , PC9-IR (pulmonary) ( 280 ) , placenta ( 536 ) , platelet-blood ( 517 ) , PLC/PRF/5 (hepatic) ( 14 , 37 ) , PLC5 ( 132 ) , QGY-7703 (hepatic) ( 37 ) , R1 ('stem, embryonic') ( 443 ) , Rat1 (fibroblast) ( 240 ) , RAW 264 (macrophage) ( 525 ) , REF52 (fibroblast) ( 247 ) , RERF-GC-1B (gastric) ( 215 ) , RKO (intestinal) ( 386 ) , RMUG-S (ovarian) ( 113 ) , SACC-83 (salivary gland) ( 191 , 192 ) , SCC12 (keratinocyte) ( 502 ) , SCH (gastric) ( 227 ) , SF9 ( 282 ) , SGC7901 (gastric) ( 30 ) , SHEP (neuron) ( 127 , 546 ) , SK-HEP-1 (endothelial) ( 132 ) , SK-LU-1 (pulmonary) ( 454 ) , SK-N-BE(2) (neural crest) ( 127 ) , skin ( 180 , 380 ) , SKNAS (neural crest) ( 127 ) , SKOV-3 (ovarian) ( 118 , 247 , 515 ) , SNU-1079 (hepatic) ( 181 ) , SNU-5 (gastric) ( 298 ) , SNU-C2B (intestinal) ( 342 , 343 ) , stem ( 17 , 239 ) , stomach ( 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 194 , 195 ) , Su.86.86 (pancreatic) ( 465 ) , SW-1573 (pulmonary) ( 230 ) , SW620 (intestinal) ( 246 , 318 , 366 , 367 , 405 , 520 ) , SW780 (bladder cell) ( 278 ) , SYF (fibroblast) ( 105 , 354 , 448 , 529 ) , T lymphocyte ( 12 ) , T47D (breast cell) ( 23 , 126 , 504 ) , T84 (intestinal) ( 249 , 438 ) , T98G (glial) ( 93 , 390 ) , THP1 (myeloid) ( 487 ) , TYK-nu (ovarian) ( 115 ) , U-118MG (glial) ( 86 , 430 ) , U-251 MG (glial) ( 75 , 495 ) , U-937 (myeloid) ( 507 ) , U2OS (bone cell) ( 36 , 51 ) , U87MG (glial) [EGFR (human), transfection] ( 122 ) , UACC-812 (breast cell) ( 275 , 276 ) , UMSCC1 (squamous) ( 57 ) , VACO432 (ovarian) ( 385 )

Upstream Regulation
Regulatory protein:
Akt1 (human) ( 52 ) , ALK1 (human) ( 54 ) , CAP1 (human) ( 48 ) , CDCP1 (human) ( 69 ) , CDK18 (human) ( 8 ) , CEACAM1 (human) ( 237 ) , CEACAM1 iso8 (human) ( 237 ) , ENG (human) ( 54 ) , FAK (human) ( 214 , 499 ) , FN1 (human) ( 133 ) , Fyn (human) ( 105 ) , girdin (human) ( 20 ) , GRP78 (human) ( 37 ) , HER2 (human) ( 27 , 155 ) , HRas (mouse) ( 75 ) , IGF1R (human) ( 159 ) , IHPK2 (human) ( 35 ) , ITGA3 (human) ( 6 ) , ITGA6 (human) ( 26 ) , ITGA9 (human) ( 6 ) , ITGB1 (human) ( 13 , 133 ) , KARS (human) ( 55 ) , Kv11.1 (human) ( 7 ) , LCN2 (human) ( 205 ) , LKB1 (human) ( 49 ) , LOX (mouse) ( 188 ) , Merlin (human) ( 307 ) , Met (human) ( 354 ) , MIEN1 (human) ( 11 ) , MYH9 (human) ( 9 ) , N-Myc (human) ( 127 ) , PAK1 (human) ( 23 ) , PAK4 (human) ( 118 ) , PIN1 (human) ( 75 ) , PKCA (human) ( 129 ) , PKCD (human) ( 129 ) , PTP4A1 (human) ( 268 ) , PTPN13 (human) ( 123 ) , PTPRA (human) ( 29 ) , PXN (human) ( 56 ) , RAC1 (human) ( 36 ) , RACK1 (human) ( 159 ) , RAP1A (human) ( 189 ) , RAP1B (human) ( 189 ) , reelin (human) ( 21 ) , SAA1 (human) ( 34 ) , SHPS1 (human) ( 122 ) , Siva (human) ( 78 ) , SLK (human) ( 155 ) , Src (human) ( 270 , 349 , 354 , 448 , 529 ) , STMN1 (human) ( 78 ) , STRAD (human) ( 49 ) , Survivin (human) ( 133 ) , syntenin (human) ( 129 ) , TXNDC12 (human) ( 30 ) , Vimentin (human) ( 31 ) , XIAP (human) ( 133 )
Putative in vivo kinases:
FAK (human) ( 52 , 106 , 247 , 451 , 513 , 531 ) , FGR (human) ( 449 , 517 ) , Met (human) ( 354 )
Kinases, in vitro:
FAK (human) ( 214 , 282 ) , Met (human) ( 354 ) , Src (human) ( 214 )
Putative upstream phosphatases:
DUSP3 (human) ( 5 ) , PTEN (human) ( 531 ) , PTP-PEST (human) ( 75 ) , PTP1B (mouse) ( 374 ) , SHP-2 (human) ( 15 )
Phosphatases, in vitro:
DUSP3 (human) ( 5 ) , PTP-PEST (human) ( 75 )
Treatments:
2-deoxyribose ( 512 ) , A-443654 ( 246 ) , AG1478 ( 122 , 438 ) , aggregation ( 495 ) , allopurinol ( 353 ) , alpha2-macroglobulin ( 37 ) , anti-CD3/CD28 ( 12 ) , anti-ITGA5 ( 512 ) , anti-ITGAv ( 512 ) , anti-ITGB1 ( 512 ) , anti-ITGB3 ( 512 ) , antimycin_A ( 353 ) , apocynin ( 353 ) , BAPTA-AM ( 438 ) , blood pressure ( 540 ) , bombesin ( 499 ) , bortezomib ( 269 ) , cabozantinib ( 24 ) , carbachol ( 249 , 438 ) , cell_adhesion ( 56 , 266 , 504 ) , cell_detachment ( 266 , 328 , 454 ) , ciclosporin ( 93 ) , collagen ( 368 ) , collagen_I ( 13 , 129 , 520 ) , collagen_IV ( 371 , 410 , 531 , 547 ) , CXCL12 ( 500 ) , cyclic_stretch ( 239 , 248 , 270 , 353 , 442 ) , cycloheximide ( 522 ) , cytochalasin_D ( 266 , 353 , 371 , 438 , 502 ) , dasatinib ( 57 ) , DDC ( 353 ) , defactinib ( 24 ) , deoxycholic_acid ( 281 ) , DIM ( 25 ) , DMSO ( 246 ) , DPI ( 353 ) , dronabinol ( 230 ) , ebselen ( 353 ) , EGF ( 230 , 249 ) , EphB1 ( 521 ) , ephrin_A1 ( 245 ) , ephrin_B2 ( 135 ) , FGF2 ( 17 ) , fibronectin ( 8 , 36 , 51 , 52 , 105 , 129 , 188 , 268 , 368 , 420 , 451 , 502 , 508 , 514 , 529 , 538 , 545 , 546 ) , fluid_shear_stress ( 530 ) , force ( 19 ) , genistein ( 438 ) , glabridin ( 74 ) , Go_6976 ( 129 , 353 ) , GPI-562 ( 517 ) , GRP ( 499 ) , H2O2 ( 353 , 380 ) , HAMLET ( 109 ) , HGF ( 3 ) , hypoxia ( 536 ) , ICAM-1 ( 12 ) , IGF-1 ( 159 , 443 , 546 ) , IL-1a ( 525 ) , insulin ( 526 ) , laminin-1 ( 55 , 368 , 538 ) , laulimalide ( 370 ) , LDL ( 517 ) , liothyronine ( 38 ) , low_potassium ( 54 ) , LPA ( 524 ) , LY294002 ( 246 , 514 , 533 ) , mannitol ( 546 ) , medium change ( 78 ) , metastatic potential ( 406 ) , MFAP5 ( 136 ) , N-nitro-L-arginine ( 353 ) , NAC ( 353 ) , nocodazole ( 78 ) , NSC23766 ( 270 ) , nystatin ( 54 ) , okadaic_acid ( 546 ) , PAO ( 531 ) , PD98059 ( 535 ) , PDGF ( 52 , 544 ) , PF-573228 ( 3 , 49 , 111 , 247 ) , PF562271 ( 24 , 25 ) , phorbol_ester ( 240 , 353 ) , pioglitazone ( 507 ) , poly-L-lysine ( 238 ) , PP1 ( 3 , 517 ) , PP2 ( 214 , 245 , 248 , 270 , 281 , 438 , 444 , 503 , 513 , 533 , 534 ) , PP3 ( 214 , 245 , 513 ) , pressure ( 246 , 487 ) , PRL ( 23 ) , RGD ( 506 , 540 ) , Ro31-8220 ( 353 ) , rotenone ( 353 ) , rottlerin ( 129 ) , SB202190 ( 56 ) , SB203580 ( 520 ) , SB431542 ( 54 ) , serum ( 530 ) , serum_starvation ( 137 ) , siRNA ( 189 , 205 , 268 ) , sphingosine_1-phosphate ( 503 ) , staurosporine ( 137 , 522 ) , TGF-beta ( 54 , 238 , 513 ) , thapsigargin ( 438 ) , thrombin ( 503 , 517 ) , thrombospondin ( 458 ) , TIMP2 ( 351 ) , TNF ( 352 ) , U0126 ( 75 ) , ultrasound ( 358 ) , vanadate ( 15 , 23 , 351 , 509 , 524 , 531 ) , VEGF ( 189 , 346 , 370 , 463 , 512 , 525 , 528 , 533 ) , vitronectin ( 538 ) , WAY_123398 ( 7 , 420 ) , wortmannin ( 449 ) , Y15 ( 14 , 127 )

Downstream Regulation
Effects of modification on FAK:
enzymatic activity, induced ( 24 , 52 , 106 , 205 , 449 , 521 , 537 , 544 ) , intracellular localization ( 442 , 527 , 537 ) , molecular association, regulation ( 22 , 31 , 495 , 537 , 544 ) , phosphorylation ( 238 , 239 , 541 ) , protein degradation ( 511 )
Effects of modification on biological processes:
apoptosis, altered ( 401 ) , apoptosis, inhibited ( 127 , 511 , 543 ) , carcinogenesis, induced ( 24 , 132 ) , carcinogenesis, inhibited ( 75 ) , cell adhesion, altered ( 5 , 127 , 159 , 205 , 307 , 458 , 512 , 522 , 531 , 544 ) , cell adhesion, induced ( 31 , 75 ) , cell adhesion, inhibited ( 52 ) , cell differentiation, altered ( 239 ) , cell growth, altered ( 106 , 159 , 495 ) , cell growth, induced ( 13 , 24 ) , cell motility, altered ( 106 , 133 , 159 , 205 , 307 , 537 ) , cell motility, induced ( 25 , 52 ) , cell motility, inhibited ( 75 ) , cytoskeletal reorganization ( 78 , 266 , 442 , 521 , 537 ) , endocytosis, altered ( 541 ) , transcription, altered ( 238 , 239 , 543 )
Induce interaction with:
FAK (human) ( 537 ) , PIK3R1 (human) ( 544 ) , RASA1 (human) ( 22 , 495 ) , Vimentin (human) ( 31 )
Inhibit interaction with:
PIK3R2 (human) ( 307 ) , Src (human) ( 307 )

Disease / Diagnostics Relevance
Relevant diseases:
colorectal cancer ( 510 ) , hepatocellular carcinoma ( 132 ) , lung cancer ( 75 ) , ovarian epithelial carcinoma ( 40 ) , cancer, squamous cell carcinoma ( 505 )

References 

1

Sato T, et al. (2020) A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction. Nat Commun 11, 3282
32612176   Curated Info

2

Ruggiero C, et al. (2018) The KDEL receptor signalling cascade targets focal adhesion kinase on focal adhesions and invadopodia. Oncotarget 9, 10228-10246
29535802   Curated Info

3

Gayrard C, et al. (2018) Src- and confinement-dependent FAK activation causes E-cadherin relaxation and β-catenin activity. J Cell Biol
29311227   Curated Info

4

Genna A, et al. (2018) Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. J Cell Biol 217, 375-395
29133485   Curated Info

5

Chen YR, et al. (2017) Deficiency in VHR/DUSP3, a suppressor of focal adhesion kinase, reveals its role in regulating cell adhesion and migration. Oncogene 36, 6509-6517
28759036   Curated Info

6

Longmate WM, et al. (2017) Suppression of integrin α3β1 by α9β1 in the epidermis controls the paracrine resolution of wound angiogenesis. J Cell Biol 216, 1473-1488
28416479   Curated Info

7

Becchetti A, et al. (2017) The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. Sci Signal 10
28377405   Curated Info

8

Matsuda S, et al. (2017) PCTK3/CDK18 regulates cell migration and adhesion by negatively modulating FAK activity. Sci Rep 7, 45545
28361970   Curated Info

9

Rai V, Thomas DG, Beach JR, Egelhoff TT (2017) Myosin IIA Heavy Chain Phosphorylation Mediates Adhesion Maturation and Protrusion in Three Dimensions. J Biol Chem 292, 3099-3111
28053086   Curated Info

10

Cheng Z, et al. (2017) Focal Adhesion Kinase-mediated Phosphorylation of Beclin1 Protein Suppresses Cardiomyocyte Autophagy and Initiates Hypertrophic Growth. J Biol Chem 292, 2065-2079
27994061   Curated Info

11

Wang Y, et al. (2017) Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth. Oncogene 36, 756-765
27399332   Curated Info

12

Eppler FJ, Quast T, Kolanus W (2017) Dynamin2 controls Rap1 activation and integrin clustering in human T lymphocyte adhesion. PLoS One 12, e0172443
28273099   Curated Info

13

Begum A, et al. (2017) The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. PLoS One 12, e0180181
28692661   Curated Info

14

Wong KF, et al. (2016) Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma. Oncotarget 7, 77683-77695
27765911   Curated Info

15

Choi I, et al. (2016) LRRK2 Inhibits FAK Activity by Promoting FERM-mediated Autoinhibition of FAK and Recruiting the Tyrosine Phosphatase, SHP-2. Exp Neurobiol 25, 269-276
27790061   Curated Info

16

Kimani SG, et al. (2016) Normalization of TAM post-receptor signaling reveals a cell invasive signature for Axl tyrosine kinase. Cell Commun Signal 14, 19
27595981   Curated Info

17

Burgett ME, et al. (2016) Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells. Oncotarget 7, 43852-43867
27270311   Curated Info

18

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

19

Scott DW, Tolbert CE, Burridge K (2016) Tension on JAM-A activates RhoA via GEF-H1 and p115 RhoGEF. Mol Biol Cell 27, 1420-30
26985018   Curated Info

20

Leyme A, Marivin A, Garcia-Marcos M (2016) GIV/Girdin (Gα-interacting, Vesicle-associated Protein/Girdin) Creates a Positive Feedback Loop That Potentiates Outside-in Integrin Signaling in Cancer Cells. J Biol Chem 291, 8269-82
26887938   Curated Info

21

Lin L, et al. (2016) Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3. Oncotarget 7, 9844-58
26848618   Curated Info

22

Antoine-Bertrand J, et al. (2016) p120RasGAP Protein Mediates Netrin-1 Protein-induced Cortical Axon Outgrowth and Guidance. J Biol Chem 291, 4589-602
26710849   Curated Info

23

Hammer A, Diakonova M (2016) Prolactin-induced PAK1 tyrosyl phosphorylation promotes FAK dephosphorylation, breast cancer cell motility, invasion and metastasis. BMC Cell Biol 17, 31
27542844   Curated Info

24

Lee YC, et al. (2015) Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res 75, 4949-59
26530902   Curated Info

25

Li WX, et al. (2015) 3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling. Oncotarget 6, 23776-92
26068982   Curated Info

26

Nam SH, et al. (2015) Noncanonical roles of membranous lysyl-tRNA synthetase in transducing cell-substrate signaling for invasive dissemination of colon cancer spheroids in 3D collagen I gels. Oncotarget 6, 21655-74
26091349   Curated Info

27

Lakshmanan I, et al. (2015) Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. Oncotarget 6, 21085-99
26035354   Curated Info

28

Ibrahim R, Lemoine A, Bertoglio J, Raingeaud J (2015) Human enhancer of filamentation 1-induced colorectal cancer cell migration: Role of serine phosphorylation and interaction with the breast cancer anti-estrogen resistance 3 protein. Int J Biochem Cell Biol 64, 45-57
25817040   Curated Info

29

Fang XQ, et al. (2015) Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase-α at Tyr789 in breast cancer cells. Mol Med Rep 11, 4303-8
25625869   Curated Info

30

Wu J, et al. (2015) ERp19 contributes to tumorigenicity in human gastric cancer by promoting cell growth, migration and invasion. Oncotarget 6, 11794-805
25940440   Curated Info

31

Havel LS, Kline ER, Salgueiro AM, Marcus AI (2015) Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene 34, 1979-90
24858039   Curated Info

32

Palacios-Moreno J, et al. (2015) Neuroblastoma Tyrosine Kinase Signaling Networks Involve FYN and LYN in Endosomes and Lipid Rafts. PLoS Comput Biol 11, e1004130
25884760   Curated Info

33

Ravi A, et al. (2015) Epidermal Growth Factor Activates the Rho GTPase-activating Protein (GAP) Deleted in Liver Cancer 1 via Focal Adhesion Kinase and Protein Phosphatase 2A. J Biol Chem 290, 4149-62
25525271   Curated Info

34

Lung HL, et al. (2015) SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma. Oncogene 34, 878-89
24608426   Curated Info

35

Rao F, et al. (2015) Inositol pyrophosphates promote tumor growth and metastasis by antagonizing liver kinase B1. Proc Natl Acad Sci U S A 112, 1773-8
25617365   Curated Info

36

Pasapera AM, et al. (2015) Rac1-Dependent Phosphorylation and Focal Adhesion Recruitment of Myosin IIA Regulates Migration and Mechanosensing. Curr Biol 25, 175-86
25544611   Curated Info

37

Zhao S, et al. (2015) The role of c-Src in the invasion and metastasis of hepatocellular carcinoma cells induced by association of cell surface GRP78 with activated α2M. BMC Cancer 15, 389
25958313   Curated Info

38

Park JW, Zhao L, Webb P, Cheng SY (2014) Src-dependent phosphorylation at Y406 on the thyroid hormone receptor β confers the tumor suppressor activity. Oncotarget 5, 10002-16
25275301   Curated Info

39

Guilluy C, et al. (2014) Isolated nuclei adapt to force and reveal a mechanotransduction pathway in the nucleus. Nat Cell Biol 16, 376-81
24609268   Curated Info

40

Aust S, et al. (2014) Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium. Mol Cancer 13, 67
24655477   Curated Info

41

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

42

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

43

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

44

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

45

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

46

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

47

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

48

Zhang H, et al. (2013) Mammalian Adenylyl Cyclase-associated Protein 1 (CAP1) Regulates Cofilin Function, the Actin Cytoskeleton, and Cell Adhesion. J Biol Chem 288, 20966-77
23737525   Curated Info

49

Kline ER, et al. (2013) LKB1 represses focal adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and directional persistence. J Biol Chem 288, 17663-74
23637231   Curated Info

50

Rikova K (2013) CST Curation Set: 18449; Year: 2012; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) MultiMab(TM) Rabbit mAb mix Cat#: 8954
Curated Info

51

Feng Y, et al. (2013) α-actinin1 and 4 tyrosine phosphorylation is critical for stress fiber establishment, maintenance and focal adhesion maturation. Exp Cell Res 319, 1124-35
23454549   Curated Info

52

Higuchi M, et al. (2013) Akt1 promotes focal adhesion disassembly and cell motility through phosphorylation of FAK in growth factor-stimulated cells. J Cell Sci 126, 745-55
23264741   Curated Info

53

Johnson H, et al. (2012) Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts. Mol Cell Proteomics 11, 1724-40
22964225   Curated Info

54

Tian H, et al. (2012) Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells. EMBO J 31, 3885-900
22940691   Curated Info

55

Kim DG, et al. (2012) Interaction of two translational components, lysyl-tRNA synthetase and p40/37LRP, in plasma membrane promotes laminin-dependent cell migration. FASEB J 26, 4142-59
22751010   Curated Info

56

Kwak TK, et al. (2012) Cell adhesion-dependent serine 85 phosphorylation of paxillin modulates focal adhesion formation and haptotactic migration via association with the C-terminal tail domain of talin. J Biol Chem 287, 27499-509
22761432   Curated Info

57

Wheeler SE, et al. (2012) Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res 18, 2850-60
22490227   Curated Info

58

Rikova K (2012) CST Curation Set: 14270; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 1mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

59

Rikova K (2012) CST Curation Set: 14271; Year: 2012; Biosample/Treatment: cell line, Tumor pilot study 2mg/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

60

Possemato A (2012) CST Curation Set: 14060; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

61

Possemato A (2012) CST Curation Set: 14061; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

62

Possemato A (2012) CST Curation Set: 14062; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

63

Possemato A (2012) CST Curation Set: 14063; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

64

Possemato A (2012) CST Curation Set: 14058; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

65

Possemato A (2012) CST Curation Set: 14059; Year: 2012; Biosample/Treatment: cell line, H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

66

Zhou J (2012) CST Curation Set: 13888; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

67

Zhou J (2012) CST Curation Set: 13889; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

68

Zhou J (2012) CST Curation Set: 13898; Year: 2012; Biosample/Treatment: cell line, MKN-45/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

69

Benes CH, Poulogiannis G, Cantley LC, Soltoff SP (2012) The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility. Oncogene 31, 653-63
21725358   Curated Info

70

Mulhern D (2012) CST Curation Set: 13331; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

71

Mulhern D (2012) CST Curation Set: 13332; Year: 2012; Biosample/Treatment: cell line, HCT 116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

72

Mulhern D (2012) CST Curation Set: 13333; Year: 2012; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Cat#: 8954, Phospho-Tyrosine Rabbit mAb (p-Tyr-1000) Immunoaffinity Beads Cat#: 8876
Curated Info

73

Tomar A, Lawson C, Ghassemian M, Schlaepfer DD (2012) Cortactin as a Target for FAK in the Regulation of Focal Adhesion Dynamics. PLoS One 7, e44041
22952866   Curated Info

74

Tsai YM, et al. (2011) Glabridin inhibits migration, invasion, and angiogenesis of human non-small cell lung cancer A549 cells by inhibiting the FAK/rho signaling pathway. Integr Cancer Ther 10, 341-9
21059620   Curated Info

75

Zheng Y, et al. (2011) Ras-Induced and Extracellular Signal-Regulated Kinase 1 and 2 Phosphorylation-Dependent Isomerization of Protein Tyrosine Phosphatase (PTP)-PEST by PIN1 Promotes FAK Dephosphorylation by PTP-PEST. Mol Cell Biol 31, 4258-69
21876001   Curated Info

76

Morello V, et al. (2011) β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells. Oncogene 30, 4087-96
21478906   Curated Info

77

Li C, et al. (2011) Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene 30, 3802-12
21478903   Curated Info

78

Li N, et al. (2011) Siva1 suppresses epithelial-mesenchymal transition and metastasis of tumor cells by inhibiting stathmin and stabilizing microtubules. Proc Natl Acad Sci U S A 108, 12851-6
21768358   Curated Info

79

Possemato A (2011) CST Curation Set: 11905; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

80

Possemato A (2011) CST Curation Set: 11906; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

81

Possemato A (2011) CST Curation Set: 11907; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

82

Possemato A (2011) CST Curation Set: 11908; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

83

Possemato A (2011) CST Curation Set: 11909; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

84

Possemato A (2011) CST Curation Set: 11911; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

85

Possemato A (2011) CST Curation Set: 11912; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

86

Possemato A (2011) CST Curation Set: 11915; Year: 2011; Biosample/Treatment: cell line, U118 MG/untreated; Disease: astrocytoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

87

Possemato A (2011) CST Curation Set: 11917; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

88

Possemato A (2011) CST Curation Set: 11918; Year: 2011; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

89

Possemato A (2011) CST Curation Set: 11919; Year: 2011; Biosample/Treatment: cell line, NCI-H3122/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

90

Possemato A (2011) CST Curation Set: 11921; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

91

Possemato A (2011) CST Curation Set: 11922; Year: 2011; Biosample/Treatment: cell line, HCC78/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

92

Possemato A (2011) CST Curation Set: 11924; Year: 2011; Biosample/Treatment: cell line, HCT116/untreated; Disease: colorectal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

93

Kwiatkowska A, et al. (2011) Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression. Biochim Biophys Acta 1813, 655-67
21276823   Curated Info

94

Ren H (2011) CST Curation Set: 11773; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

95

Ren H (2011) CST Curation Set: 11778; Year: 2011; Biosample/Treatment: cell line, RP95/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

96

Ren H (2011) CST Curation Set: 11784; Year: 2011; Biosample/Treatment: cell line, RP101/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

97

Ren H (2011) CST Curation Set: 11785; Year: 2011; Biosample/Treatment: cell line, RP102/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

98

Ren H (2011) CST Curation Set: 11787; Year: 2011; Biosample/Treatment: cell line, RP104/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

99

Ren H (2011) CST Curation Set: 11791; Year: 2011; Biosample/Treatment: cell line, FAC 13T/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

100

Deramaudt TB, et al. (2011) FAK phosphorylation at Tyr-925 regulates cross-talk between focal adhesion turnover and cell protrusion. Mol Biol Cell 22, 964-75
21289086   Curated Info

101

Kuo JC, et al. (2011) Analysis of the myosin-II-responsive focal adhesion proteome reveals a role for β-Pix in negative regulation of focal adhesion maturation. Nat Cell Biol 13, 383-93
21423176   Curated Info

102

Li Y (2011) CST Curation Set: 10524; Year: 2011; Biosample/Treatment: tissue, heart/untreated; Disease: ventricular tachycardia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

103

Chumbalkar V, et al. (2011) Analysis of Phosphotyrosine Signaling in Glioblastoma Identifies STAT5 as a Novel Downstream Target of ΔEGFR. J Proteome Res 10, 1343-52
21214269   Curated Info

104

Ren H (2011) CST Curation Set: 11303; Year: 2011; Biosample/Treatment: cell line, OVMANA/serum starved; Disease: ovarian epithelial carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

105

Yeo MG, et al. (2011) Phosphorylation of Ser 21 in Fyn regulates its kinase activity, focal adhesion targeting, and is required for cell migration. J Cell Physiol 226, 236-47
20658524   Curated Info

106

Chen TH, Chan PC, Chen CL, Chen HC (2011) Phosphorylation of focal adhesion kinase on tyrosine 194 by Met leads to its activation through relief of autoinhibition. Oncogene 30, 153-66
20802513   Curated Info

107

Gu TL, et al. (2011) Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 6, e15640
21253578   Curated Info

108

Ding VM, et al. (2011) Tyrosine phosphorylation profiling in fgf-2 stimulated human embryonic stem cells. PLoS One 6, e17538
21437283   Curated Info

109

Trulsson M, et al. (2011) HAMLET binding to α-actinin facilitates tumor cell detachment. PLoS One 6, e17179
21408150   Curated Info

110

Wang W, Liu Y, Liao K (2011) Tyrosine phosphorylation of cortactin by the FAK-Src complex at focal adhesions regulates cell motility. BMC Cell Biol 12, 49
22078467   Curated Info

111

Ocak S, et al. (2010) DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway. Oncogene 29, 6331-42
20802517   Curated Info

112

Ren H (2010) CST Curation Set: 10743; Year: 2010; Biosample/Treatment: cell line, OVKATE/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

113

Ren H (2010) CST Curation Set: 10753; Year: 2010; Biosample/Treatment: cell line, RMUG-S/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

114

Ren H (2010) CST Curation Set: 10754; Year: 2010; Biosample/Treatment: cell line, OVMIU/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

115

Ren H (2010) CST Curation Set: 10751; Year: 2010; Biosample/Treatment: cell line, TYK-nu/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

116

Ren H (2010) CST Curation Set: 10756; Year: 2010; Biosample/Treatment: cell line, OVCAR8/serum starved; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

117

Knowlton ML, et al. (2010) Profiling Y561-Dependent and -Independent Substrates of CSF-1R in Epithelial Cells. PLoS One 5, e13587
21049007   Curated Info

118

Siu MK, et al. (2010) p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients. Proc Natl Acad Sci U S A 107, 18622-7
20926745   Curated Info

119

Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72
20562096   Curated Info

120

Ren H (2010) CST Curation Set: 10180; Year: 2010; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411
Curated Info

121

Tucker M (2010) CST Curation Set: 10091; Year: 2010; Biosample/Treatment: cell line, OVCAR8/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

122

Kapoor GS, O'Rourke DM (2010) SIRPalpha1 receptors interfere with the EGFRvIII signalosome to inhibit glioblastoma cell transformation and migration. Oncogene 29, 4130-44
20473329   Curated Info

123

Glondu-Lassis M, et al. (2010) PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase. Cancer Res 70, 5116-26
20501847   Curated Info

124

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

125

Li J, et al. (2010) A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 6, 291-9
20190765   Curated Info

126

Heinrich C, et al. (2010) Copine-III interacts with ErbB2 and promotes tumor cell migration. Oncogene 29, 1598-610
20010870   Curated Info

127

Beierle EA, et al. (2010) Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma. Cell Cycle 9, 1005-15
20160475   Curated Info

128

Hu Y (2010) CST Curation Set: 8708; Year: 2010; Biosample/Treatment: tissue, lung/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

129

Hwangbo C, Kim J, Lee JJ, Lee JH (2010) Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/Syntenin. Cancer Res 70, 1645-55
20145126   Curated Info

130

Zhou J (2010) CST Curation Set: 9107; Year: 2010; Biosample/Treatment: cell line, NTERA-2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-102) Cat#: 9416
Curated Info

131

Ren H (2010) CST Curation Set: 9100; Year: 2010; Biosample/Treatment: cell line, FU97/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

132

Chen JS, et al. (2010) FAK is involved in invasion and metastasis of hepatocellular carcinoma. Clin Exp Metastasis 27, 71-82
20180147   Curated Info

133

Mehrotra S, et al. (2010) IAP regulation of metastasis. Cancer Cell 17, 53-64
20129247   Curated Info

134

Moritz A, et al. (2010) Akt-RSK-S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases. Sci Signal 3, ra64
20736484   Curated Info

135

Jørgensen C, et al. (2009) Cell-specific information processing in segregating populations of Eph receptor ephrin-expressing cells. Science 326, 1502-9
20007894   Curated Info

136

Mok SC, et al. (2009) A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 16, 521-32
19962670   Curated Info

137

Fanucchi S, Veale RB (2009) Role of p53/FAK association and p53Ser46 phosphorylation in staurosporine-mediated apoptosis: wild type versus mutant p53-R175H. FEBS Lett 583, 3557-62
19857493   Curated Info

138

Ren H (2009) CST Curation Set: 8327; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

139

Tucker M (2009) CST Curation Set: 8067; Year: 2009; Biosample/Treatment: cell line, LN444/untreated; Disease: glioblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

140

Ren H (2009) CST Curation Set: 8058; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

141

Ren H (2009) CST Curation Set: 8059; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

142

Ren H (2009) CST Curation Set: 8060; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

143

Ren H (2009) CST Curation Set: 8055; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

144

Ren H (2009) CST Curation Set: 8025; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

145

Ren H (2009) CST Curation Set: 8024; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

146

Ren H (2009) CST Curation Set: 8020; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

147

Ren H (2009) CST Curation Set: 8018; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

148

Moritz A (2009) CST Curation Set: 7848; Year: 2009; Biosample/Treatment: cell line, Cell Mix/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

149

Moritz A (2009) CST Curation Set: 7849; Year: 2009; Biosample/Treatment: cell line, NCI-H441/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

150

Moritz A (2009) CST Curation Set: 7813; Year: 2009; Biosample/Treatment: cell line, NCI-H23/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

151

Moritz A (2009) CST Curation Set: 7814; Year: 2009; Biosample/Treatment: cell line, NCI-H358/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

152

Moritz A (2009) CST Curation Set: 7815; Year: 2009; Biosample/Treatment: cell line, PANC-1/untreated; Disease: pancreatic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

153

Moritz A (2009) CST Curation Set: 7817; Year: 2009; Biosample/Treatment: cell line, HPAC/untreated; Disease: pancreatic carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

154

Gu T (2009) CST Curation Set: 7583; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

155

Roovers K, et al. (2009) The Ste20-like kinase SLK is required for ErbB2-driven breast cancer cell motility. Oncogene 28, 2839-48
19525980   Curated Info

156

Gu T (2009) CST Curation Set: 7537; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

157

Gu T (2009) CST Curation Set: 7521; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

158

Gu T (2009) CST Curation Set: 7522; Year: 2009; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

159

Kiely PA, et al. (2009) Phosphorylation of RACK1 on Tyrosine 52 by c-Abl Is Required for Insulin-like Growth Factor I-mediated Regulation of Focal Adhesion Kinase. J Biol Chem 284, 20263-74
19423701   Curated Info

160

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

161

Tucker M (2009) CST Curation Set: 7354; Year: 2009; Biosample/Treatment: cell line, HLF/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

162

Tucker M (2009) CST Curation Set: 7353; Year: 2009; Biosample/Treatment: cell line, HepG2/untreated; Disease: hepatocellular carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

163

Moritz A (2009) CST Curation Set: 7288; Year: 2009; Biosample/Treatment: cell line, A549/untreated; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

164

Moritz A (2009) CST Curation Set: 7284; Year: 2009; Biosample/Treatment: cell line, NCI-H1650/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

165

Moritz A (2009) CST Curation Set: 7286; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

166

Ren H (2009) CST Curation Set: 7178; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

167

Ren H (2009) CST Curation Set: 7174; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

168

Ren H (2009) CST Curation Set: 6960; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

169

Moritz A (2009) CST Curation Set: 7219; Year: 2009; Biosample/Treatment: cell line, BT-474/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

170

Possemato A (2009) CST Curation Set: 7157; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

171

Possemato A (2009) CST Curation Set: 7156; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

172

Possemato A (2009) CST Curation Set: 7154; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

173

Gu T (2009) CST Curation Set: 7078; Year: 2009; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

174

Gu T (2009) CST Curation Set: 7039; Year: 2009; Biosample/Treatment: tissue, esophagus/untreated; Disease: esophageal cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

175

Gu T (2009) CST Curation Set: 6577; Year: 2009; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

176

Tucker M (2009) CST Curation Set: 6661; Year: 2009; Biosample/Treatment: cell line, Huh1/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

177

Ren H (2009) CST Curation Set: 6483; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

178

Ren H (2009) CST Curation Set: 6478; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

179

Ren H (2009) CST Curation Set: 6477; Year: 2009; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell squamous cell lung carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

180

Tucker M (2009) CST Curation Set: 6393; Year: 2009; Biosample/Treatment: tissue, skin/untreated; Disease: melanoma skin cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

181

Tucker M (2009) CST Curation Set: 6388; Year: 2009; Biosample/Treatment: cell line, SNU-1079/untreated; Disease: bile-duct cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

182

Tucker M (2009) CST Curation Set: 5975; Year: 2009; Biosample/Treatment: cell line, JHH-6/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

183

Moritz A (2009) CST Curation Set: 5954; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

184

Moritz A (2009) CST Curation Set: 5955; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

185

Moritz A (2009) CST Curation Set: 5956; Year: 2009; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

186

Tucker M (2009) CST Curation Set: 5961; Year: 2009; Biosample/Treatment: cell line, JHH-5/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

187

Tucker M (2009) CST Curation Set: 5949; Year: 2009; Biosample/Treatment: cell line, NOZ/untreated; Disease: gallbladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

188

Zhao Y, et al. (2009) The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells. J Biol Chem 284, 1385-93
19029090   Curated Info

189

Carmona G, et al. (2009) Role of the small GTPase Rap1 for integrin activity regulation in endothelial cells and angiogenesis. Blood 113, 488-97
18805968   Curated Info

190

Stokes M (2008) CST Curation Set: 5669; Year: 2008; Biosample/Treatment: cell line, ACC-S/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

191

Stokes M (2008) CST Curation Set: 5671; Year: 2008; Biosample/Treatment: cell line, SACC-83/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

192

Stokes M (2008) CST Curation Set: 5670; Year: 2008; Biosample/Treatment: cell line, SACC-83/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

193

Stokes M (2008) CST Curation Set: 5675; Year: 2008; Biosample/Treatment: cell line, HUVEC/VEGF-121; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

194

Ren H (2008) CST Curation Set: 5584; Year: 2008; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

195

Ren H (2008) CST Curation Set: 5627; Year: 2008; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

196

Ren H (2008) CST Curation Set: 5496; Year: 2008; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

197

Tucker M (2008) CST Curation Set: 5425; Year: 2008; Biosample/Treatment: cell line, Huh6/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

198

Moritz A (2008) CST Curation Set: 5385; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

199

Rikova K (2008) CST Curation Set: 5372; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

200

Rikova K (2008) CST Curation Set: 5327; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

201

Rikova K (2008) CST Curation Set: 5328; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

202

Moritz A (2008) CST Curation Set: 5056; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

203

Moritz A (2008) CST Curation Set: 5057; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

204

Moritz A (2008) CST Curation Set: 5082; Year: 2008; Biosample/Treatment: cell line, HeLa/nocodazole; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

205

Tong Z, et al. (2008) Neutrophil gelatinase-associated lipocalin: a novel suppressor of invasion and angiogenesis in pancreatic cancer. Cancer Res 68, 6100-8
18676832   Curated Info

206

Gu T (2008) CST Curation Set: 4851; Year: 2008; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

207

Gu T (2008) CST Curation Set: 4848; Year: 2008; Biosample/Treatment: liver, para-hepatocellular carcinoma tissue, hepatic/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

208

Gu T (2008) CST Curation Set: 4849; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

209

Gu T (2008) CST Curation Set: 4754; Year: 2008; Biosample/Treatment: liver, hepatocyte/untreated; Disease: liver cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

210

Rikova K (2008) CST Curation Set: 4482; Year: 2008; Biosample/Treatment: cell line, MGH- sarcoma pat/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

211

Rikova K (2008) CST Curation Set: 4433; Year: 2008; Biosample/Treatment: cell line, A549/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

212

Rikova K (2008) CST Curation Set: 4434; Year: 2008; Biosample/Treatment: cell line, A549 LKB Dana F/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

213

Stokes M (2008) CST Curation Set: 4143; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

214

Wu L, et al. (2008) Distinct FAK-Src activation events promote alpha5beta1 and alpha4beta1 integrin-stimulated neuroblastoma cell motility. Oncogene 27, 1439-48
17828307   Curated Info

215

Ren H (2008) CST Curation Set: 3921; Year: 2008; Biosample/Treatment: cell line, RERF-GC-1B/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

216

Ren H (2008) CST Curation Set: 3915; Year: 2008; Biosample/Treatment: cell line, AZ-521/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

217

Ren H (2008) CST Curation Set: 3917; Year: 2008; Biosample/Treatment: cell line, IM95/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

218

Ren H (2008) CST Curation Set: 3918; Year: 2008; Biosample/Treatment: cell line, MKN-1/serum starved; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

219

Ren H (2008) CST Curation Set: 3919; Year: 2008; Biosample/Treatment: cell line, NUGC-3/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

220

Stokes M (2008) CST Curation Set: 3884; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY])
Curated Info

221

Possemato A (2008) CST Curation Set: 3822; Year: 2008; Biosample/Treatment: cell line, Jurkat/pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

222

Moritz A (2008) CST Curation Set: 3803; Year: 2008; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

223

Ren H (2008) CST Curation Set: 3790; Year: 2008; Biosample/Treatment: cell line, NUGC-2/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

224

Ren H (2008) CST Curation Set: 3791; Year: 2008; Biosample/Treatment: cell line, NUGC-4/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

225

Ren H (2008) CST Curation Set: 3792; Year: 2008; Biosample/Treatment: cell line, MKN-7/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

226

Ren H (2008) CST Curation Set: 3793; Year: 2008; Biosample/Treatment: cell line, MKN-74/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

227

Ren H (2008) CST Curation Set: 3794; Year: 2008; Biosample/Treatment: cell line, SCH/serum starved; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

228

Possemato A (2008) CST Curation Set: 3781; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

229

Guo A, et al. (2008) Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 105, 692-7
18180459   Curated Info

230

Preet A, Ganju RK, Groopman JE (2008) Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. Oncogene 27, 339-46
17621270   Curated Info

231

Possemato A (2008) CST Curation Set: 3642; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

232

Possemato A (2007) CST Curation Set: 3626; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

233

Possemato A (2007) CST Curation Set: 3597; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

234

Rikova K, et al. (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131, 1190-203
18083107   Curated Info

235

Stokes M (2007) CST Curation Set: 3554; Year: 2007; Biosample/Treatment: cell line, HOS/serum starved; Disease: bone cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

236

Stokes M (2007) CST Curation Set: 3553; Year: 2007; Biosample/Treatment: cell line, 143B/serum starved; Disease: osteosarcoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

237

Yokoyama S, Chen CJ, Nguyen T, Shively JE (2007) Role of CEACAM1 isoforms in an in vivo model of mammary morphogenesis: mutational analysis of the cytoplasmic domain of CEACAM1-4S reveals key residues involved in lumen formation. Oncogene 26, 7637-46
17546042   Curated Info

238

Hayashida T, et al. (2007) MAP-kinase activity necessary for TGFbeta1-stimulated mesangial cell type I collagen expression requires adhesion-dependent phosphorylation of FAK tyrosine 397. J Cell Sci 120, 4230-40
18032789   Curated Info

239

Ward DF, et al. (2007) Focal adhesion kinase signaling controls cyclic tensile strain enhanced collagen I-induced osteogenic differentiation of human mesenchymal stem cells. Mol Cell Biomech 4, 177-88
18437915   Curated Info

240

Villa-Moruzzi E (2007) Targeting of FAK Ser910 by ERK5 and PP1delta in non-stimulated and phorbol ester-stimulated cells. Biochem J 408, 7-18
17692050   Curated Info

241

Ren H (2007) CST Curation Set: 3473; Year: 2007; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

242

Ren H (2007) CST Curation Set: 3443; Year: 2007; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

243

Ren H (2007) CST Curation Set: 3386; Year: 2007; Biosample/Treatment: tissue, ovary/untreated; Disease: ovarian cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

244

Stokes M (2007) CST Curation Set: 3239; Year: 2007; Biosample/Treatment: cell line, 143.98.2/serum starved; Disease: osteosarcoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

245

Parri M, et al. (2007) EphrinA1 activates a Src/focal adhesion kinase-mediated motility response leading to rho-dependent actino/myosin contractility. J Biol Chem 282, 19619-28
17449913   Curated Info

246

Thamilselvan V, Craig DH, Basson MD (2007) FAK association with multiple signal proteins mediates pressure-induced colon cancer cell adhesion via a Src-dependent PI3K/Akt pathway. FASEB J 21, 1730-41
17317726   Curated Info

247

Slack-Davis JK, et al. (2007) Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 282, 14845-52
17395594   Curated Info

248

Chaturvedi LS, Marsh HM, Basson MD (2007) Src and focal adhesion kinase mediate mechanical strain-induced proliferation and ERK1/2 phosphorylation in human H441 pulmonary epithelial cells. Am J Physiol Cell Physiol 292, C1701-13
17215324   Curated Info

249

Jiang X, Sinnett-Smith J, Rozengurt E (2007) Differential FAK phosphorylation at Ser-910, Ser-843 and Tyr-397 induced by angiotensin II, LPA and EGF in intestinal epithelial cells. Cell Signal 19, 1000-10
17240116   Curated Info

250

Rikova K (2007) CST Curation Set: 2867; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

251

Rikova K (2007) CST Curation Set: 2870; Year: 2007; Biosample/Treatment: cell line, A549/serum starved; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

252

Rikova K (2007) CST Curation Set: 2871; Year: 2007; Biosample/Treatment: cell line, A549/serum starved; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

253

Rikova K (2007) CST Curation Set: 2872; Year: 2007; Biosample/Treatment: cell line, A549/serum starved; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

254

Rikova K (2007) CST Curation Set: 2873; Year: 2007; Biosample/Treatment: cell line, HCC827/serum starved; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

255

Guo A (2007) CST Curation Set: 2780; Year: 2007; Biosample/Treatment: cell line, MKN-45/Su11274; Disease: gastric carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

256

Moritz A (2007) CST Curation Set: 2767; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/Gleevec; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

257

Moritz A (2007) CST Curation Set: 2772; Year: 2007; Biosample/Treatment: cell line, NCI-H1703/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

258

Moritz A (2007) CST Curation Set: 2777; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/Iressa; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

259

Moritz A (2007) CST Curation Set: 2778; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

260

Wissing J, et al. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry. Mol Cell Proteomics 6, 537-47
17192257   Curated Info

261

Li Y (2007) CST Curation Set: 2488; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

262

Li Y (2007) CST Curation Set: 2489; Year: 2007; Biosample/Treatment: cell line, NCI-H3255/untreated &'||' Geldanamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

263

Li Y (2007) CST Curation Set: 2490; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

264

Li Y (2007) CST Curation Set: 2491; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated &'||' Geldanamycin; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

265

Li Y (2007) CST Curation Set: 2492; Year: 2007; Biosample/Treatment: cell line, HCC827/untreated &'||' TSA; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

266

Jacamo R, Jiang X, Lunn JA, Rozengurt E (2007) FAK phosphorylation at Ser-843 inhibits Tyr-397 phosphorylation, cell spreading and migration. J Cell Physiol 210, 436-44
17096371   Curated Info

267

Rikova K (2007) CST Curation Set: 2308; Year: 2007; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

268

Achiwa H, Lazo JS (2007) PRL-1 tyrosine phosphatase regulates c-Src levels, adherence, and invasion in human lung cancer cells. Cancer Res 67, 643-50
17234774   Curated Info

269

Lorch JH, Thomas TO, Schmoll HJ (2007) Bortezomib inhibits cell-cell adhesion and cell migration and enhances epidermal growth factor receptor inhibitor-induced cell death in squamous cell cancer. Cancer Res 67, 727-34
17234784   Curated Info

270

Chaturvedi LS, et al. (2007) Repetitive deformation activates focal adhesion kinase and ERK mitogenic signals in human Caco-2 intestinal epithelial cells through Src and Rac1. J Biol Chem 282, 14-28
17088251   Curated Info

271

Rikova K (2007) CST Curation Set: 2204; Year: 2007; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

272

Michaud C (2006) CST Curation Set: 2170; Year: 2006; Biosample/Treatment: tissue, lung/-; Disease: lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

273

Rikova K (2006) CST Curation Set: 2159; Year: 2006; Biosample/Treatment: tissue, lung/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

274

Michaud C (2006) CST Curation Set: 2107; Year: 2006; Biosample/Treatment: cell line, HCC1599/0.5% serum; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

275

Michaud C (2006) CST Curation Set: 2109; Year: 2006; Biosample/Treatment: cell line, UACC-812/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

276

Michaud C (2006) CST Curation Set: 2110; Year: 2006; Biosample/Treatment: cell line, UACC-812/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

277

Rikova K (2006) CST Curation Set: 2101; Year: 2006; Biosample/Treatment: cell line, 639L/serum starved; Disease: kidney cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

278

Rikova K (2006) CST Curation Set: 2103; Year: 2006; Biosample/Treatment: cell line, SW780/serum starved; Disease: bladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

279

Rikova K (2006) CST Curation Set: 2106; Year: 2006; Biosample/Treatment: cell line, CAL-29/serum starved; Disease: bladder cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

280

Guo A (2006) CST Curation Set: 2089; Year: 2006; Biosample/Treatment: cell line, PC9-IR/-; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

281

Khare S, Holgren C, Samarel AM (2006) Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase ShP2. Am J Physiol Gastrointest Liver Physiol 291, G1100-12
16920701   Curated Info

282

Ciccimaro E, Hevko J, Blair IA (2006) Analysis of phosphorylation sites on focal adhesion kinase using nanospray liquid chromatography/multiple reaction monitoring mass spectrometry. Rapid Commun Mass Spectrom 20, 3681-92
17117420   Curated Info

283

Stokes M (2006) CST Curation Set: 2042; Year: 2006; Biosample/Treatment: cell line, GI-CA-N/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

284

Stokes M (2006) CST Curation Set: 2043; Year: 2006; Biosample/Treatment: cell line, LAN-1/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

285

Michaud C (2006) CST Curation Set: 1986; Year: 2006; Biosample/Treatment: cell line, AU565/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

286

Michaud C (2006) CST Curation Set: 1987; Year: 2006; Biosample/Treatment: cell line, AU565/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

287

Michaud C (2006) CST Curation Set: 1988; Year: 2006; Biosample/Treatment: cell line, CAL-51/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

288

Michaud C (2006) CST Curation Set: 1989; Year: 2006; Biosample/Treatment: cell line, CAL-51/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

289

Michaud C (2006) CST Curation Set: 1992; Year: 2006; Biosample/Treatment: cell line, HCC70/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

290

Michaud C (2006) CST Curation Set: 1993; Year: 2006; Biosample/Treatment: cell line, HCC70/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

291

Michaud C (2006) CST Curation Set: 1994; Year: 2006; Biosample/Treatment: cell line, MT-3/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

292

Michaud C (2006) CST Curation Set: 1995; Year: 2006; Biosample/Treatment: cell line, MT-3/serum starved; Disease: breast cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

293

Stokes M (2006) CST Curation Set: 1946; Year: 2006; Biosample/Treatment: cell line, GI-ME-N/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

294

Stokes M (2006) CST Curation Set: 1944; Year: 2006; Biosample/Treatment: cell line, ACN/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

295

Stokes M (2006) CST Curation Set: 1945; Year: 2006; Biosample/Treatment: cell line, GI-LI-N/serum starved; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411,